[{"orgOrder":0,"company":"Jixing Pharmaceuticals","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Series D Financing","leadProduct":"Aficamten","moa":"Cardiac myosin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Jixing Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jixing Pharmaceuticals \/ Bayer AG","highestDevelopmentStatusID":"10","companyTruncated":"Jixing Pharmaceuticals \/ Bayer AG"}]

Find Clinical Drug Pipeline Developments & Deals by Jixing Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Plastics Recycling EU
                          Not Confirmed
                          Plastics Recycling EU
                          Not Confirmed

                          Details :

                          Product Name : CK-3773274

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 01, 2024

                          Lead Product(s) : Aficamten

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Phase III

                          Sponsor : Bayer AG

                          Deal Size : $162.0 million

                          Deal Type : Series D Financing

                          blank